Trial Profile

A Phase 1 pharmacokinetics study of COBENFY (xanomeline and trospium chloride) in China

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trospium chloride/xanomeline (Primary)
Indications Schizophrenia
Focus Pharmacokinetics

Most Recent Events

07 Jan 2026 New trial record
23 Dec 2025 According to Zai Lab media release, company announced that Chinas National Medical Products Administration (NMPA) approved the New Drug Application (NDA) for COBENFY (xanomeline and trospium chloride) for the treatment of schizophrenia in adults.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com